Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy

• Published in: Cancer medicine (Malden, MA) MA), 2024-10, Vol.13 (19), p.e70168-n/a
• Main Authors: Wu, Xiao‐Gang, Liu, Wei, Wang, Yan‐Yan, Wang, Kun, Xing, Bao‐Cai
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Cancer therapies; Chemotherapy; Codon; Codons; Colorectal cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Colorectal Neoplasms - surgery; Female; GTP Phosphohydrolases - genetics; Hepatectomy; Humans; Liver; liver metastasis; Liver Neoplasms - genetics; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Magnetic resonance imaging; Male; Medical prognosis; Membrane Proteins - genetics; Metastases; Metastasis; Middle Aged; Multivariate analysis; Mutation; Normal distribution; Patients; Prognosis; Proto-Oncogene Proteins p21(ras) - genetics; RAS codon mutation; Retrospective Studies; Risk factors; Risk groups; Statistical analysis; Surgery; Survival; Tumors
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.70168

Purpose The prognostic and predictive value of RAS mutations in patients with colorectal liver metastases (CRLM) who have undergone hepatectomy holds substantial importance. The present study aimed to investigate the impact of different RAS codon mutations on long‐term survival in CRLM patients. Methods A retrospective analysis was conducted on clinicopathological data from 399 CRLM patients with RAS mutations who underwent hepatectomy between January 2000 and December 2020. The RAS mutation gene status was assessed in KRAS codons (G12, G13, Q61, and A146) and NRAS codons (G12, G13, and Q61). Survival curves were generated using the Kaplan–Meier plotter and compared using the log‐rank test. Univariate and multivariate analyses were performed to analyze the clinicopathological data. Results In the entire cohort, patients with KRAS G12 mutations exhibited the most favorable prognosis (p = 0.018). Comparatively, patients harboring KRAS Q61 mutations experienced poorer overall survival (OS) with a median of 15 months versus 33 months (p = 0.011) when compared to those with KRAS G12 mutations. Moreover, patients with NRAS Q61 mutations also showed decreased OS with a median of 26 months versus 33 months (p = 0.020) in comparison to KRAS G12 mutation patients. The results of multivariate analysis showed that both KRAS Q61 mutation (HR 2.130; 95% CI 1.088–4.168; p = 0.027) and NRAS Q61 mutation (HR 2.877; 95% CI 1.398–5.922; p = 0.004) were independent influencing factors of OS. Based on all identified risk factors, patients with RAS mutation were divided into high‐risk and low‐risk groups. Notably, in the high‐risk group, the incorporation of postoperative chemotherapy was associated with longer OS, while it did not improve the survival of patients in the low‐risk group. Conclusions KRAS Q61 and NRAS Q61 mutations are promising predictors for OS in CRLM patients after hepatectomy. Postoperative chemotherapy may significantly benefit CRLM patients with RAS mutations, particularly those identified as high‐risk.